Dimeric recombinant IgA directed against carcino-embryonic antigen, a novel tool for carcinoma localization.
Mol Immunol
; 31(17): 1313-9, 1994 Dec.
Article
em En
| MEDLINE
| ID: mdl-7997243
ABSTRACT
Carcinoembryonic antigen (CEA) has been shown to be one of the best markers for in vivo tumor targeting of radiolabeled antibodies, despite the fact that it is localized predominantly at the apical side of human colon carcinoma cells within the fairly closed pseudolumen structures formed by these tumors. Due to this particular histological localization, a large proportion of the CEA molecules may remain inaccessible to the intravenously injected radiolabeled anti-CEA antibodies of IgG isotype, which are widely used in the clinic. In order to improve targeting, we made a recombinant dimeric IgA, which should have the capacity to translocate from the basolateral to the apical side of the pseudolumen formed by colon carcinoma cells after binding to the polyIg receptor (pIgR). A genomic chimeric mouse-human IgA2 construct was made using one of our most specific anti-CEA hybridomas, CE-25. The chimeric IgA (chIgA) was expressed in the Sp2/0 myeloma cell line. The secreted recombinant antibody was found to consist mostly of a dimeric form of IgA with a molecular weight of about 350 kDa. The dimeric chIgA was shown to translocate efficiently in vitro across a monolayer of epithelial cells expressing the pIgR and to retain full CEA binding activity.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Proteínas Recombinantes de Fusão
/
Imunoglobulina A
/
Antígeno Carcinoembrionário
/
Anticorpos Antineoplásicos
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Mol Immunol
Ano de publicação:
1994
Tipo de documento:
Article
País de afiliação:
Suíça